GLP-1 and muscle

Does it work?

• -The muscle loss is real, and it's the part of the GLP-1 conversation that matters most to lifters. Across randomized trials, roughly a quarter to two fifths of the weight lost on semaglutide or tirzepatide is not fat: a 2026 systematic review put the median at about 28% of total weight lost, above the expected benchmark in two thirds of the trials it reviewed. One review estimated participants shed 10% or more of their muscle across 68–72 weeks — about what twenty years of aging costs you. None of that is an argument against the drugs. It is an argument for lifting and eating protein while you're on one.

How to apply

• -Keep lifting. Resistance training is the single most effective countermeasure to muscle loss during rapid weight loss, and every review of incretin therapy converges on it.
• -Hit protein deliberately. Appetite suppression makes 1.2–1.6 g/kg/day almost impossible to reach by accident; on a small total intake, protein has to be prioritized ahead of everything else on the plate.
• -Don't chase the fastest possible loss. Slower titration and a smaller deficit cost less lean mass for the same eventual result.
• -Judge progress by strength, not by the scale. If your working weights fall week over week, you're losing more than fat.
• -Keep training through the plateau and after you stop. Muscle lost during the drop is what makes weight regain come back as fat.

The catch

• -The percentages sound worse than they read in context. Some fat-free mass loss accompanies any weight loss, and body composition improves overall — lean mass as a share of body weight actually rises. The concern is absolute muscle lost, which was largest with semaglutide in meta-analysis, around −5.4 kg.
• -Almost none of the trials measured physical function. We know the tissue goes; we mostly don't know what it cost people in strength, power, or day-to-day capacity.
• -The evidence for the fix is largely borrowed from non-drug weight-loss research. Well-powered trials of resistance training and protein specifically during incretin therapy are still thin on the ground.

Safety

• -This is a prescription-medication topic. Whether to take one, at what dose, and how fast to titrate are decisions for you and your doctor — not for a training app.
• -Rapid weight loss on a low protein intake risks bone and muscle together. Older adults and anyone already low on muscle are the most exposed.
• -If strength is dropping fast, stairs feel hard, or nausea is keeping your intake very low, that's a reason to talk to your prescriber — not a reason to push harder in the gym.

Key research

• Effect of Incretin-Based and Nonpharmacologic Weight Loss on Body Composition: A Systematic ReviewAnn Intern Med · 2026 · Systematic review
• Effect of GLP-1 receptor agonists at doses for obesity management on muscle health: systematic review and meta-analysis of randomized controlled trialsInt J Obes · 2026 · Meta-analysis
• Strategies for minimizing muscle loss during use of incretin-mimetic drugs for treatment of obesityObes Rev · 2025 · Review
• Characterizing body composition modifying effects of a glucagon-like peptide 1 receptor-based agonist: A meta-analysisDiabetes Obes Metab · 2025 · Meta-analysis

Related